Health Risks of Supraphysiologic Testosterone in Transgender Men
Supraphysiologic testosterone doses in transgender men significantly increase the risk of erythrocytosis/polycythemia, cardiovascular events including thrombosis, and adverse metabolic changes—risks that are largely avoidable by maintaining testosterone levels within the normal physiological male range (350-700 ng/dL). 1
Primary Risks of Excessive Testosterone Dosing
The Endocrine Society explicitly warns that the risk of cross-sex hormone therapy arises from and is worsened by inadvertent or intentional use of supraphysiological doses 1. The key adverse outcomes include:
Hematologic Complications
- Erythrocytosis/Polycythemia: The most consistently documented risk, with hemoglobin increases of 4.9-12.5% and hematocrit increases of 4.4-17.6% reported 2
- Thrombotic events: A documented case of branch retinal artery occlusion occurred in a 45-year-old transgender man self-administering 250mg weekly testosterone enanthate (supraphysiologic dosing), who developed hemoglobin of 19.3 g/dL and hematocrit of 62% 3
- This represents a hypercoagulable state that can lead to arterial and venous thrombosis 4
Cardiovascular Risks
Cardiovascular events are disproportionately represented in adverse event reports for transgender men on testosterone 5:
- Pulmonary embolism occurred in 50% of reported cardiovascular cases
- Median time to onset was 34 months
- Notably, these events occurred in men aged 21-40 years—younger than typical cardiovascular risk populations 5
Mechanistic cardiovascular changes include 6:
- Increased leukocyte-endothelium interactions
- Elevated adhesion molecules (VCAM-1, E-selectin)
- Increased proinflammatory cytokines (IL-6, TNF-alpha)
- Reduced HDL cholesterol and increased atherogenic index
Metabolic Derangements
Over 10 years of testosterone therapy, even at physiologic dosing, transgender men experience 7:
- Worsening lipid profiles: LDL, total cholesterol, and triglycerides increase; HDL decreases throughout treatment
- Increased BMI (1.3-11.4%), waist circumference, and shift to android fat distribution
- Increased metabolic syndrome prevalence by female criteria
- However, fasting glucose and blood pressure showed minimal changes 7
Hepatic Effects
- Up to 15% of transgender men on testosterone develop transient liver enzyme elevations 1
- Serious hepatic toxicity is rare with parenteral or transdermal formulations (oral 17-alkylated testosterone is not recommended) 1
Critical Monitoring to Prevent Supraphysiologic Complications
The Endocrine Society guideline provides specific testosterone target ranges and monitoring schedules 1:
Testosterone Level Targets
- Target range: 350-700 ng/dL (normal physiological male range)
- For testosterone enanthate/cypionate injections: measure midway between injections
- Adjust dose if levels are >700 ng/dL or <350 ng/dL
Monitoring Schedule
- Complete blood count: Every 3 months for the first year, then 1-2 times yearly 1
- Liver function tests: Same schedule as CBC
- Lipids, fasting glucose, hemoglobin A1c (if diabetic): At regular visits
- Weight and blood pressure: At every visit
Important Caveat
During the first 3-9 months of treatment, total testosterone levels may appear high while free testosterone levels are normal due to elevated SHBG in some biological females 1. This is a transient phenomenon and should not be mistaken for true supraphysiologic dosing.
Evidence Quality and Cardiovascular Mortality
A critical limitation exists in the evidence base: A systematic review found data were insufficient (very low quality evidence) to meaningfully assess death, stroke, myocardial infarction, or venous thromboembolism in transgender men 1. Long-term Dutch cohort studies found no increased cardiovascular mortality, but these studies had limitations 1.
More recent data show 34 cardiovascular deaths among 7,837 transgender men (1.81 per 1,000 person-years), though certainty of evidence remains low to very low 8. A 10-year cohort study recorded no major cardiovascular events but noted one case of atrial fibrillation 7.
Clinical Pitfalls to Avoid
Self-administration of supraphysiologic doses: The case of retinal artery occlusion demonstrates the danger of unregulated testosterone use at 250mg weekly (far exceeding standard dosing) 3
Inadequate monitoring: Failure to check CBC regularly can miss dangerous erythrocytosis before thrombotic complications occur
Ignoring cardiovascular risk factors: Even young transgender men (21-40 years) can develop cardiovascular events, particularly with supraphysiologic dosing 5
Misinterpreting early elevated total testosterone: Remember that SHBG elevation in the first 3-9 months can artificially elevate total testosterone while free testosterone remains normal 1
Risk Mitigation Strategy
Maintain testosterone in the physiological male range (350-700 ng/dL) through appropriate dosing and monitoring 1. When levels exceed this range:
- Reduce testosterone dose immediately
- Increase monitoring frequency for hematocrit (target <52%)
- Assess for signs/symptoms of thrombosis
- Evaluate cardiovascular risk factors and manage according to established guidelines 1
The evidence consistently shows that adverse outcomes are associated with supraphysiologic dosing, while physiologic testosterone replacement appears safer, though long-term cardiovascular data remain limited 1, 4, 5.